【摘要】 目的分析雌激素受体(ER)、孕激素受体(PR)及人类表皮生长因子受体2(Her-2)在乳腺导管原位癌(DCIS)、导管原位癌伴微浸润(DCIS-Mi)和浸润性导管癌(IDC)中的表达情况,为深入研究DCIS-Mi奠定基础。方法收集解放军307医院2002年10月-2013年2月经病理学确诊的30例DCIS、51例DCIS-Mi及49例IDC的病理标本,采用免疫组织化学染色法检测ER、PR及Her-2在DCIS、DCIS-Mi、IDC中的表达情况。结果以≥10%肿瘤细胞核着色为阳性界值:在DCIS、DCIS-Mi及IDC中,ER阳性率分别为63.33%、41.18%、79.59%(P<0.001),PR阳性率分别为53.33%、37.25%、61.22%(P=0.052);以≥1%肿瘤细胞核着色为阳性界值:在DCIS、DCIS-Mi及IDC中,ER阳性率分别为66.67%、52.94%、83.67%(P<0.01),PR阳性率分别为66.67%、47.06%、75.51%(P<0.01)。Her-2在DCIS、DCIS-Mi及IDC中的阳性率分别为26.67%、27.45%、18.37%(P=0.520)。ER在Ⅰ、Ⅱ级DCIS中的阳性率高于Ⅲ级,PR在Ⅰ级DCIS中的阳性率高于Ⅱ、Ⅲ级,Her-2在Ⅰ、Ⅱ级DCIS中的阳性率低于Ⅲ级,差异均有统计学意义(P<0.05)。结论 DCIS-Mi的分子生物学和遗传学改变可能不同于DCIS和IDC。DCIS中ER、PR及Her-2的表达与组织学分级密切相关,这种差异可能与乳腺癌发生发展不同阶段中的遗传学表现不同有关。更多还原

【Abstract】 Objective To analyze the variations of ER, PR and HER-2 in breast ductal carcinoma in situ(DCIS), DCIS with micro-invasive(DCIS-Mi), and invasive ductal carcinoma(IDC) to establish a basis for further study on DCIS-Mi. MethodsThe samples of 30 DCIS, 51 DCIS-Mi and 49 IDC diagnosed by pathology from patients hospitalized in 307 hospital of PLA from October 2002 to February 2013, were collected in the present study. The expressions of ER, PR and Her-2 in breast DCIS, DCISMi and IDC were determined by immunohistochemical staining method. Results When ≥10% tumor nuclei were colored, it was judged as positive, the expressions of ER in DCIS, DCIS-Mi and IDC were found to be 63.33%, 41.18% and 79.59%(P<0.001), and of PR were 53.33%, 37.25% and 61.22%(P=0.052). Judged to be positive when ≥1% tumor nuclei were colored, the expressions of ER in DCIS, DCIS-Mi and IDC were found to be 66.67%, 52.94% and 83.67%(P<0.01), and of PR were 66.67%, 47.06% and 75.51%(P=0.012). The expressions of Her-2 in DCIS, IDC and DCIS-Mi were 26.67%, 27.45% and 18.37% respectively(P=0.012). The expressions of ER in DCIS classⅠ and Ⅱ were higher than that in class Ⅲ, the expression of PR in DCIS class Ⅰ was higher than that in class Ⅱ and Ⅲ, and the expressions of Her-2 in DCIS classⅠ and Ⅱ were lower than that in class Ⅲ(P<0.05). Conclusions There are probably different molecular biological and genetical changes in DCIS-Mi from DCIS and IDC. The expressions of ER, PR and Her-2 in DCIS are closely correlated with the histological grading, and the differences may be related to different genetic expressions in different stages of breast cancer development.更多还原